FBR-002
/ Fab’entech
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
April 04, 2022
Safety and Pharmacokinetics of FBR-002 for the Treatment of Patients Hospitalized With COVID-19 in Need of Supplemental Oxygen and at Risk of Severe Outcome
(clinicaltrials.gov)
- P2a | N=30 | Recruiting | Sponsor: Fab'entech | Not yet recruiting ➔ Recruiting
Enrollment open • Infectious Disease • Novel Coronavirus Disease • Solid Tumor
March 15, 2022
Safety and Pharmacokinetics of FBR-002 for the Treatment of Patients Hospitalized With COVID-19 in Need of Supplemental Oxygen and at Risk of Severe Outcome
(clinicaltrials.gov)
- P2a | N=30 | Not yet recruiting | Sponsor: Fab'entech
New P2a trial • Infectious Disease • Novel Coronavirus Disease • Solid Tumor
1 to 2
Of
2
Go to page
1